<DOC>
	<DOCNO>NCT00813267</DOCNO>
	<brief_summary>Mesenchymal Stem Cells ( MSCs ) show immunosuppressive repairing property . Bone marrow mononuclear cell ( BMMNCs ) revascularization property complimentary effect MSCs . The investigator infuse expand autologous MSCs BMMNCs patient osteonecrosis femoral head . The study purpose examine whether treatment result improvement osteonecrosis femoral head .</brief_summary>
	<brief_title>Mesenchymal Stem Cell Osteonecrosis Femoral Head</brief_title>
	<detailed_description>Mesenchymal Stem Cells ( MSCs ) show immunosuppressive repairing property . Bone marrow mononuclear cell ( BMMNCs ) revascularization property complimentary effect MSCs . Patients study receive infusion expand autologous MSC BMMNCs . The puncture femoral artery conduct digital subtraction angiography ( DSA ) , tubes insert medial femoral circumflex artery , lateral femoral circumflex artery obturatou artey . The study evaluate safety effectiveness MSC infusion patient osteonecrosis femoral head . This study last 5 year . Patients undergo infusion Day 0 . Afterward , patient evaluate response , undergo X-ray examination , CT MR scan 6-month interval .</detailed_description>
	<mesh_term>Osteonecrosis</mesh_term>
	<mesh_term>Osteochondritis</mesh_term>
	<criteria>Ages : 12 60 year old . Association Research Circulation Osseous ( ARCO ) Classification criterion osteonecrosis femoral head : ARCO phase I phase II . Able give inform consent . Pregnant woman . Previous history malignancy Active infection include hepatitis B , hepatitis C , HIV , TB determine positive skin test clinical presentation , treatment suspect TB . Evidence cardiovascular disease , exist congestive cardiac failure physical exam and/or acute coronary syndrome past 6 month . Psychiatric illness mental deficiency make compliance treatment inform consent impossible . Any illness opinion investigator would jeopardize ability Patient tolerate treatment .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Mesenchymal Stem Cells</keyword>
	<keyword>Osteonecrosis Femoral Head</keyword>
</DOC>